Recent

% | $
Quotes you view appear here for quick access.

Arena Pharmaceuticals, Inc. Message Board

  • tgallo5726 tgallo5726 Jul 19, 2013 2:24 PM Flag

    aace guidelines

    aacedotcomslashfilesslashconsensusdashstatementdotpdf

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Thanks for posting link and for taking the time to post the pertinent information from the guidelines.
      Daniel
      UCLA MD

      Sentiment: Strong Buy

    • Prediabetes
      Prediabetes reflects failing pancreatic compensation
      to an underlying state of insulin resistance, most commonly caused by excess body weight or obesity. Current
      criteria for the diagnosis of prediabetes include impaired
      glucose tolerance, impaired fasting glucose, or metabolic
      syndrome. (See Comprehensive Diabetes Management
      Algorithm-Prediabetes Algorithm). Any one of these factors is associated with a 5-fold increase in future T2DM
      risk (12).
      The primary goal of prediabetes management is
      weight loss. Whether achieved through TLC, pharmacotherapy, surgery, or some combination thereof, weight loss
      reduces insulin resistance and can effectively prevent progression to diabetes as well as improve lipids and blood
      pressure. However, weight loss may not directly address
      the pathogenesis of declining beta-cell function. When
      indicated, bariatric surgery can also be highly effective in
      preventing progression to diabetes (12).

      • 1 Reply to tgallo5726
      • oss medications can
        be used in combination with lifestyle modification for all
        patients with a BMI ≥27 kg/m2
        and comorbidities. In 2012,
        the U.S. Food and Drug Administration approved 2 drugs,
        lorcaserin and phentermine/topiramate extended-release
        (ER), as adjuncts to lifestyle modification in overweight/
        obese patients. In clinical trials, both drugs were associated with placebo-subtracted weight loss (lorcaserin, 3.6%;
        phentermine/topiramate ER, 9.7%) after 1 year of treatment. Both drugs improved blood pressure, triglycerides,

 
ARNA
4.31-0.06(-1.37%)Apr 1 4:00 PMEDT